Table 1.
BASDAI 50 response at 3 months in biologic-naïve patients
| Administration | Treatment | Biologic-naïve |
|---|---|---|
| Subcutaneous | Secukinumab | 41.53% |
| Certolizumab pegol | 44.20% | |
| Etanercept | 36.80% | |
| Adalimumab | 48.85% | |
| Golimumab | 47.20% | |
| Intravenous | Infliximab | 44.20% |
Notes: BASDAI 50 response data are from a Bayesian fixed effects network meta-analysis.22 Biologic-naïve data for certolizumab pegol and infliximab were not available and were assumed equivalent to average of other biologics in the network meta-analysis
Abbreviation: BASDAI, Bath Ankylosing Spondylitis Disease Activity Index.